Pathologic implications of dysregulated pulmonary vascular metabolism to pulmonary arterial hypertension (PAH) are increasingly recognized, but their clinical applications have been limited. We hypothesized that metabolite quantification across the pulmonary vascular bed in connective tissue disease–associated (CTD-associated) PAH would identify transpulmonary gradients of pathobiologically relevant metabolites, in an exercise stage–specific manner. Sixty-three CTD patients with established or suspected PAH underwent exercise right heart catheterization. Using mass spectrometry–based metabolomics, metabolites were quantified in plasma samples simultaneously collected from the pulmonary and radial arteries at baseline and during resistance-free wheeling, peak exercise, and recovery. We identified uptake and excretion of metabolites across the pulmonary vascular bed, unique and distinct from single vascular site analysis. We demonstrated the physiological relevance of metabolites previously shown to promote disease in animal models and end-stage human lung tissues, including acylcarnitines, glycolytic intermediates, and tryptophan catabolites. Notably, pulmonary vascular metabolite handling was exercise stage specific. Transpulmonary metabolite gradients correlated with hemodynamic endpoints largely during free-wheeling. Glycolytic intermediates demonstrated physiologic significance at peak exercise, including net uptake of lactate in those with more advanced disease. Contribution of pulmonary vascular metabolism to CTD-PAH pathogenesis and therapeutic candidacy of metabolism modulation must be considered in the context of physiologic stress.
Michael H. Lee, Thaís C. F. Menezes, Julie A. Reisz, Francesca I. Cendali, Eloara V. M. Ferreira, Jaquelina S. Ota-Arakaki, Priscila A. Sperandio, Rahul Kumar, Claudia Mickael, Martin M. Ieong, Juliana Lucena Santos, Ana Carolina B. Duarte, Dara C. Fonseca Balladares, Kevin Nolan, Rubin M. Tuder, Paul M. Hassoun, Angelo D’Alessandro, Rudolf K. F. Oliveira, Brian B. Graham
Usage data is cumulative from May 2025 through December 2025.
| Usage | JCI | PMC |
|---|---|---|
| Text version | 1,411 | 143 |
| 306 | 54 | |
| Figure | 493 | 0 |
| Table | 123 | 0 |
| Supplemental data | 149 | 9 |
| Citation downloads | 79 | 0 |
| Totals | 2,561 | 206 |
| Total Views | 2,767 | |
Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.
Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.